Blair Leavitt

MD

Investigator, BC Children's Hospital
Senior Scientist, CMMT

My laboratory develops new treatments for neurodevelopmental disorders such as pyridoxine dependent epilepsy and neurodegenerative diseases such as Huntington's disease. We do this by first developing transgenic mouse models of specific human diseases, and then by testing new disease treatments in these mouse models. The YAC128 mouse model of Huntington's disease accurately replicates the changes seen in humans with this disease, and is a critical tool that permits my laboratory to evaluate new treatment strategies in mice prior to undertaking large-scale clinical trials in human patients. My work was initially focused on transgenic mouse models of Huntington's disease, but has now expanded to utilize the same standardized approach to investigate new therapeutics in mouse models of other devastating neurodevelopmental and neurodegenerative disorders, such as Frontotemporal dementia and Fragile X syndrome.

Academic Affiliations

  • Professor, , Department of Medical Genetics, Faculty of Medicine, University of British Columbia
  • Research Theme: Brain, Behaviour & Development
  • Research Group(s): Neurodevelopmental and Neurological Disorders

Contact Information

Assistant

Angela Gurney

awilkes@cmmt.ubc.ca

Location

950 West 28th Avenue, Vancouver, British Columbia, Canada, V5Z 4H4

Emerging roles of microglia and neuroinflammation in Huntington's disease: From pathophysiology to clinical trials

Journal of Huntington's Disease

Muna Abedrabbo and Pardis Kazemian and Colm Connolly and Blair R Leavitt

DOI: 10.1177/18796397251330144

08 / 2025

Progranulin function and regulation in the CNS

Trends in Neurosciences

Benjamin E. Life and Blair R. Leavitt

DOI: 10.1016/j.tins.2025.05.004

07 / 2025

Progressive alterations in white matter microstructure across the timecourse of Huntington's disease

Brain and Behavior

Carlos Estevez-Fraga and Michael S. Elmalem and Marina Papoutsi and Alexandra Durr and Elin M. Rees and Nicola Z. Hobbs and Raymund A. C. Roos and Bernhard Landwehrmeyer and Blair R. Leavitt and Douglas R. Langbehn and Rachael I. Scahill and Geraint Rees and Sarah J. Tabrizi and Sarah Gregory

DOI: 10.1002/brb3.2940

04 / 2023

Progranulin is an FMRP target that influences macroorchidism but not behaviour in a mouse model of Fragile X Syndrome

Current Research in Neurobiology

Benjamin Life and Luis E.B. Bettio and Ilse Gantois and Brian R. Christie and Blair R. Leavitt

DOI: 10.1016/j.crneur.2023.100094

Huntingtin Over-Expression Does Not Alter Overall Survival in Murine Cancer Models

Laura Chan and Austin Hill and Ge Lu and Jeremy Van Raamsdonk and Randy D. Gascoyne and Michael R. Hayden and Blair R. Leavitt

DOI: 10.1101/2022.09.11.507440

09 / 2022

Author Correction: The current landscape of nucleic acid therapeutics

Nature Nanotechnology

Jayesh A. Kulkarni and Dominik Witzigmann and Sarah B. Thomson and Sam Chen and Blair R. Leavitt and Pieter R. Cullis and Roy van der Meel

DOI: 10.1038/s41565-021-00937-w

07 / 2021

Safety and feasibility of research lumbar puncture in Huntingtons disease: the HDClarity cohort and bioresource

Filipe B Rodrigues and Gail Owen and Swati Sathe and Elena Pak and Dipinder Kaur and Anka G Ehrhardt and Sherry Lifer and Jenny Townhill and Katarzyna Schubert and Blair R Leavitt and Mark Guttman and Jee Bang and Jan Lewerenz and Jamie Levey and Cristina Sampaio and Edward J Wild

DOI: 10.1101/2021.07.30.21261340

07 / 2021

The current landscape of nucleic acid therapeutics

Nature Nanotechnology

Jayesh A. Kulkarni and Dominik Witzigmann and Sarah B. Thomson and Sam Chen and Blair R. Leavitt and Pieter R. Cullis and Roy van der Meel

DOI: 10.1038/s41565-021-00898-0

06 / 2021

Composite UHDRS Correlates With Progression of Imaging Biomarkers in Huntington's Disease

Movement Disorders

Carlos Estevez-Fraga and Rachael I. Scahill and Alexandra Durr and Blair R. Leavitt and Raymund A.C. Roos and Douglas R. Langbehn and Geraint Rees and Sarah Gregory and Sarah J. Tabrizi

DOI: 10.1002/mds.28489

05 / 2021

Huntingtin-Lowering Therapies for Huntington Disease: A Review of the Evidence of Potential Benefits and Risks.

JAMA neurology

DOI: 10.1001/jamaneurol.2020.0299 PubMed: 32202594

03 / 2020

Early deficits in olfaction are associated with structural and molecular alterations in the olfactory system of a Huntington disease mouse model

Human molecular genetics

Laroche, M and Lessard-Beaudoin, M and Garcia-Miralles, M and Kreidy, C and Peachey, Emma and Leavitt, Blair R and Pouladi, MA and Graham, RK

DOI: 10.1093/hmg/ddaa099

Spontaneous, solvent-free entrapment of siRNA within lipid nanoparticles

Nanoscale

Jayesh A. Kulkarni and Sarah B. Thomson and Josh Zaifman and Jerry Leung and Pamela K. Wagner and Austin Hill and Yuen Yi C. Tam and Pieter R. Cullis and Terri L. Petkau and Blair R. Leavitt

DOI: 10.1039/D0NR06816K

Apathy predicts rate of cognitive decline over 24 months in premanifest Huntington's disease

Psychological medicine

Andrews, SC and Langbehn, DR and Craufurd, D and Durr, A and Leavitt, BR and Roos, RA and Tabrizi, SJ and Stout, JC and {TRACK-HD Investigators}

DOI: 10.1017/s0033291720000094

Longitudinal Structural MRI in Neurologically Healthy Adults

Journal of magnetic resonance imaging : JMRI

Gregory, Sarah and Lohse, Keith R and Johnson, Eileanoir B and Leavitt, Blair R and Durr, Alexandra and Roos, Raymund A C and Rees, Geraint and Tabrizi, Sarah J and Scahill, Rachael I and Orth, Michael

DOI: 10.1002/jmri.27203

Antisense oligonucleotides for neurodegeneration

Science (New York, N.Y.)

Leavitt, Blair R and Tabrizi, Sarah J

DOI: 10.1126/science.aba4624

A genetic association study of glutamine-encoding DNA sequence structures, somatic CAG expansion, and DNA repair gene variants, with Huntington disease clinical outcomes.

EBioMedicine

DOI: 10.1016/j.ebiom.2019.09.020 PubMed: 31607598

10 / 2019

Association of CAG Repeats With Long-term Progression in Huntington Disease.

JAMA neurology

DOI: 10.1001/jamaneurol.2019.2368 PubMed: 31403680

08 / 2019

Targeting Huntingtin Expression in Patients with Huntington's Disease.

The New England journal of medicine

DOI: 10.1056/nejmoa1900907 PubMed: 31059641

05 / 2019

Isolating cells from adult murine brain for validation of cell-type specific cre-mediated deletion

Journal of neuroscience methods

Kosior, Natalia and Petkau, Terri L and Connolly, Colm and Lu, Ge and Leavitt, Blair R

DOI: 10.1016/j.jneumeth.2019.108422

Mutant huntingtin expression in microglia is neither required nor sufficient to cause the Huntington's disease-like phenotype in BACHD mice

Human molecular genetics

Petkau, Terri L and Hill, Austin and Connolly, Colm and Lu, Ge and Wagner, Pam and Kosior, Natalia and Blanco, Jake and Leavitt, Blair R

DOI: 10.1093/hmg/ddz009

Movement Disorder Society Task Force Viewpoint: Huntington's Disease Diagnostic Categories

Movement Disorders Clinical Practice

Ross, Christopher A and Reilmann, Ralf and Cardoso, Francisco and McCusker, Elizabeth A and Testa, Claudia M and Stout, Julie C and Leavitt, Blair R and Pei, Zhong and Landwehrmeyer, Bernhard and Martinez, Asuncion and Levey, Jamie and Srajer, Teresa and Bang, Jee and Tabrizi, Sarah J

DOI: 10.1002/mdc3.12808

Huntingtin Lowering Strategies for Disease Modification in Huntington's Disease

Neuron

Tabrizi, Sarah J and Ghosh, Rhia and Leavitt, Blair R

DOI: 10.1016/j.neuron.2019.01.039

Executive impairment is associated with unawareness of neuropsychiatric symptoms in premanifest and early Huntingtons disease.

Neuropsychology

Sophie C. Andrews and David Craufurd and Alexandra Durr and Blair R. Leavitt and Raymund A. Roos and Sarah J. Tabrizi and Julie C. Stout

DOI: 10.1037/neu0000479

11 / 2018

Computational Analysis of Transcriptional Regulation Sites at the HTT Gene Locus.

Journal of Huntington's disease

DOI: 10.3233/jhd-170272 PubMed: 30103339

01 / 2018

Neurofilament light protein in blood predicts regional atrophy in Huntington disease.

Neurology

DOI: 10.1212/wnl.0000000000005005 PubMed: 29367444

01 / 2018

Brain Regions Showing White Matter Loss inHuntington's Disease Are Enriched for Synaptic and Metabolic Genes

Biological Psychiatry

McColgan, Peter and Gregory, Sarah and Seunarine, Kiran K and Razi, Adeel and Papoutsi, Marina and Johnson, Eileanoir and Durr, Alexandra and Roos, Raymund A C and Leavitt, Blair R and Holmans, Peter and Scahill, Rachael I and Clark, Chris A and Rees, Geraint and Tabrizi, Sarah J and {Track-On HD Investigators}

DOI: 10.1016/j.biopsych.2017.10.019

Murine Models of Huntington's Disease for Evaluating Therapeutics

Methods in molecular biology (Clifton, N.J.)

Kosior, Natalia and Leavitt, Blair R

DOI: 10.1007/978-1-4939-7825-0_10

Cross-sectional and longitudinal voxel-based grey matter asymmetries in Huntington's disease

NeuroImage. Clinical

Minkova, Lora and Gregory, Sarah and Scahill, Rachael I and Abdulkadir, Ahmed and Kaller, Christoph P and Peter, Jessica and Long, Jeffrey D and Stout, Julie C and Reilmann, Ralf and Roos, Raymund A and Durr, Alexandra and Leavitt, Blair R and Tabrizi, Sarah J and Klppel, Stefan and {TRACK-HD Investigators}

DOI: 10.1016/j.nicl.2017.10.023

Altered Intracortical T1-Weighted/T2-Weighted Ratio Signal in Huntington's Disease

Frontiers in neuroscience

Rowley, Christopher D and Tabrizi, Sarah J and Scahill, Rachael I and Leavitt, Blair R and Roos, Raymund A C and Durr, Alexandra and Bock, Nicholas A

DOI: 10.3389/fnins.2018.00805

Testing a longitudinal compensation model in premanifest Huntington's disease

Brain : a journal of neurology

Gregory, Sarah and Long, Jeffrey D and Klppel, Stefan and Razi, Adeel and Scheller, Elisa and Minkova, Lora and Johnson, Eileanoir B and Durr, Alexandra and Roos, Raymund A C and Leavitt, Blair R and Mills, James A and Stout, Julie C and Scahill, Rachael I and Tabrizi, Sarah J and Rees, Geraint and {Track-On investigators}

DOI: 10.1093/brain/awy122

Transcriptional Regulation of the Huntingtin Gene

Journal of Huntington's disease

Thomson, Sarah B and Leavitt, Blair R

DOI: 10.3233/jhd-180331

Editorial on Clinical Trial's Corner

Journal of Huntington's disease

Thompson, Leslie and Leavitt, Blair R

DOI: 10.3233/jhd-189000

Survival End Points for Huntington Disease Trials Prior to a Motor Diagnosis.

JAMA neurology

DOI: 10.1001/jamaneurol.2017.2107 PubMed: 28975278

11 / 2017

Selective depletion of microglial progranulin in mice is not sufficient to cause neuronal ceroid lipofuscinosis or neuroinflammation.

Journal of neuroinflammation

DOI: 10.1186/s12974-017-1000-9 PubMed: 29149899

11 / 2017

Design optimization for clinical trials in early-stage manifest Huntington's disease.

Movement disorders : official journal of the Movement Disorder Society

DOI: 10.1002/mds.27122 PubMed: 28906031

09 / 2017

KEAP1-modifying small molecule reveals muted NRF2 signaling responses in neural stem cells from Huntington's disease patients.

Proceedings of the National Academy of Sciences of the United States of America

DOI: 10.1073/pnas.1614943114 PubMed: 28533375

05 / 2017

p35 hemizygosity activates Akt but does not improve motor function in the YAC128 mouse model of Huntington's disease.

Neuroscience

DOI: 10.1016/j.neuroscience.2017.03.051 PubMed: 28391013

04 / 2017

Structural and functional brain network correlates of depressive symptoms in premanifest Huntington's disease.

Human brain mapping

DOI: 10.1002/hbm.23527 PubMed: 28294457

03 / 2017

Validation of Ultrasensitive Mutant Huntingtin Detection in Human Cerebrospinal Fluid by Single Molecule Counting Immunoassay.

Journal of Huntington's disease

DOI: 10.3233/jhd-170269 PubMed: 29125493

01 / 2017

White matter predicts functional connectivity in premanifest Huntington's disease.

Annals of clinical and translational neurology

DOI: 10.1002/acn3.384 PubMed: 28168210

01 / 2017

Recommendations for the Use of Automated Gray Matter Segmentation Tools: Evidence from Huntington's Disease

Frontiers in neurology

Johnson, Eileanoir B and Gregory, Sarah and Johnson, Hans J and Durr, Alexandra and Leavitt, Blair R and Roos, Raymund A and Rees, Geraint and Tabrizi, Sarah J and Scahill, Rachael I

DOI: 10.3389/fneur.2017.00519

Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis

The Lancet. Neurology

Byrne, Lauren M and Rodrigues, Filipe B and Blennow, Kaj and Durr, Alexandra and Leavitt, Blair R and Roos, Raymund A C and Scahill, Rachael I and Tabrizi, Sarah J and Zetterberg, Henrik and Langbehn, Douglas and Wild, Edward J

DOI: 10.1016/s1474-4422(17)30124-2

Introducing the "Clinical Trials Corner"

Journal of Huntington's disease

Leavitt, Blair R and Thompson, Leslie M

DOI: 10.3233/jhd-179003

Operationalizing compensation over time in neurodegenerative disease

Brain : a journal of neurology

Gregory, Sarah and Long, Jeffrey D and Klppel, Stefan and Razi, Adeel and Scheller, Elisa and Minkova, Lora and Papoutsi, Marina and Mills, James A and Durr, Alexandra and Leavitt, Blair R and Roos, Raymund A C and Stout, Julie C and Scahill, Rachael I and Langbehn, Douglas R and Tabrizi, Sarah J and Rees, Geraint

DOI: 10.1093/brain/awx022

Motor, cognitive, and functional declines contribute to a single progressive factor in early HD

Neurology

Schobel, Scott A and Palermo, Giuseppe and Auinger, Peggy and Long, Jeffrey D and Ma, Shiyang and Khwaja, Omar S and Trundell, Dylan and Cudkowicz, Merit and Hersch, Steven and Sampaio, Cristina and Dorsey, E Ray and Leavitt, Blair R and Kieburtz, Karl D and Sevigny, Jeffrey J and Langbehn, Douglas R and Tabrizi, Sarah J and {TRACK-HD, COHORT, CARE-HD, and 2CARE Huntington Study Group Investigators}

DOI: 10.1212/wnl.0000000000004743

Epidemiology of Huntington disease

Handbook of clinical neurology

Kay, Chris and Hayden, Michael R and Leavitt, Blair R

DOI: 10.1016/b978-0-12-801893-4.00003-1

Topological length of white matter connections predicts their rate of atrophy in premanifest Huntington's disease

JCI insight

McColgan, Peter and Seunarine, Kiran K and Gregory, Sarah and Razi, Adeel and Papoutsi, Marina and Long, Jeffrey D and Mills, James A and Johnson, Eileanoir and Durr, Alexandra and Roos, Raymund Ac and Leavitt, Blair R and Stout, Julie C and Scahill, Rachael I and Clark, Chris A and Rees, Geraint and Tabrizi, Sarah J and {Track-On HD Investigators}

DOI: 10.1172/jci.insight.92641

The reliability of commonly used electrophysiology measures

Brain stimulation

Brown, KE and Lohse, KR and Mayer, IMS and Strigaro, G and Desikan, M and Casula, EP and Meunier, S and Popa, T and Lamy, J-C and Odish, O and Leavitt, BR and Durr, A and Roos, RAC and Tabrizi, SJ and Rothwell, JC and Boyd, LA and Orth, M

DOI: 10.1016/j.brs.2017.07.011

Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study

The Lancet. Neurology

Moss, Davina J Hensman and Pardias, Antonio F and Langbehn, Douglas and Lo, Kitty and Leavitt, Blair R and Roos, Raymund and Durr, Alexandra and Mead, Simon and {TRACK-HD investigators} and {REGISTRY investigators} and Holmans, Peter and Jones, Lesley and Tabrizi, Sarah J

DOI: 10.1016/s1474-4422(17)30161-8

Conditional loss of progranulin in neurons is not sufficient to cause neuronal ceroid lipofuscinosis-like neuropathology in mice

Neurobiology of disease

Petkau, Terri L and Blanco, Jake and Leavitt, Blair R

DOI: 10.1016/j.nbd.2017.06.012

Potential biomarkers to follow the progression and treatment response of Huntington's disease.

The Journal of experimental medicine

DOI: 10.1084/jem.20160776 PubMed: 27821553

11 / 2016

Natural variation in sensory-motor white matter organization influences manifestations of Huntington's disease.

Human brain mapping

DOI: 10.1002/hbm.23332 PubMed: 27477323

08 / 2016

Visuospatial Processing Deficits Linked to Posterior Brain Regions in Premanifest and Early Stage Huntington's Disease.

Journal of the International Neuropsychological Society : JINS

DOI: 10.1017/s1355617716000321 PubMed: 27211109

05 / 2016

Enhanced immune response to MMP3 stimulation in microglia expressing mutant huntingtin.

Neuroscience

DOI: 10.1016/j.neuroscience.2016.03.031 PubMed: 27033979

03 / 2016

DNA methylation profiling in human Huntington's disease brain

Human molecular genetics

De Souza, Rebecca A G and Islam, Sumaiya A and McEwen, Lisa M and Mathelier, Anthony and Hill, Austin and Mah, Sarah M and Wasserman, Wyeth W and Kobor, Michael S and Leavitt, Blair R

DOI: 10.1093/hmg/ddw076

Cerebrospinal fluid total tau concentration predicts clinical phenotype in Huntington's disease

Journal of neurochemistry

Rodrigues, Filipe Brogueira and Byrne, Lauren and McColgan, Peter and Robertson, Nicola and Tabrizi, Sarah J and Leavitt, Blair R and Zetterberg, Henrik and Wild, Edward J

DOI: 10.1111/jnc.13719

Core neuropathological abnormalities in progranulin-deficient mice are penetrant on multiple genetic backgrounds.

Neuroscience

DOI: 10.1016/j.neuroscience.2015.12.006 PubMed: 26701296

12 / 2015

Large-scale brain network abnormalities in Huntington's disease revealed by structural covariance.

Human Brain Mapping

DOI: 10.1002/hbm.23014 PubMed: 26453902

10 / 2015

Compensation in Preclinical Huntington's Disease: Evidence From the Track-On HD Study.

EBioMedicine

DOI: 10.1016/j.ebiom.2015.08.002 PubMed: 26629536

08 / 2015

Direct intracerebral delivery of a miR-33 antisense oligonucleotide into mouse brain increases brain ABCA1 expression. [Corrected].

Neuroscience letters

DOI: 10.1016/j.neulet.2015.05.007 PubMed: 25957561

05 / 2015

Neurobiology of Huntington's Disease.

Current topics in behavioral neurosciences

DOI: 10.1007/7854_2014_353 PubMed: 25205327

01 / 2015

Reliability and factor structure of the Short Problem Behaviors Assessment for Huntington's disease (PBA-s) in the TRACK-HD and REGISTRY studies.

The Journal of neuropsychiatry and clinical neurosciences

DOI: 10.1176/appi.neuropsych.13070169 PubMed: 25716488

01 / 2015

Indoleamine 2,3 Dioxygenase as a Potential Therapeutic Target in Huntington's Disease

Journal of Huntington's disease

Mazarei, Gelareh and Leavitt, Blair R

DOI: 10.3233/jhd-159003

Detection of Motor Changes in Huntington's Disease Using Dynamic Causal Modeling

Frontiers in human neuroscience

Minkova, Lora and Scheller, Elisa and Peter, Jessica and Abdulkadir, Ahmed and Kaller, Christoph P and Roos, Raymund A and Durr, Alexandra and Leavitt, Blair R and Tabrizi, Sarah J and Klppel, Stefan and {TrackOn-HD Investigators}

DOI: 10.3389/fnhum.2015.00634

Treatment of Huntington Disease and Comorbid Trichotillomania With Aripiprazole

The Journal of neuropsychiatry and clinical neurosciences

Howard, Andrew K and Krishnamoorthy, Ashok and Leavitt, Blair R and Raymond, Lynn A and Weissman, Cory R

DOI: 10.1176/appi.neuropsych.14090232

A longitudinal study of magnetic resonance spectroscopy Huntington's disease biomarkers

Movement disorders : official journal of the Movement Disorder Society

Sturrock, Aaron and Laule, Corree and Wyper, Katy and Milner, Ruth A and Decolongon, Joji and Dar Santos, Rachelle and Coleman, Allison J and Carter, Kimberley and Creighton, Susan and Bechtel, Natalie and Bohlen, Stefan and Reilmann, Ralf and Johnson, Hans J and Hayden, Michael R and Tabrizi, Sarah J and Mackay, Alex L and Leavitt, Blair R

DOI: 10.1002/mds.26118

A SNP in the HTT promoter alters NF-B binding and is a bidirectional genetic modifier of Huntington disease

Nature neuroscience

Becanovic, Kristina and Nrremlle, Anne and Neal, Scott J and Kay, Chris and Collins, Jennifer A and Arenillas, David and Lilja, Tobias and Gaudenzi, Giulia and Manoharan, Shiana and Doty, Crystal N and Beck, Jessalyn and Lahiri, Nayana and Portales-Casamar, Elodie and Warby, Simon C and Connolly, Colm and De Souza, Rebecca A G and {REGISTRY Investigators of the European Huntington's Disease Network} and Tabrizi, Sarah J and Hermanson, Ola and Langbehn, Douglas R and Hayden, Michael R and Wasserman, Wyeth W and Leavitt, Blair R

DOI: 10.1038/nn.4014

Ultrasensitive measurement of huntingtin protein in cerebrospinal fluid demonstrates increase with Huntington disease stage and decrease following brain huntingtin suppression

Scientific reports

Southwell, Amber L and Smith, Stephen E P and Davis, Tessa R and Caron, Nicholas S and Villanueva, Erika B and Xie, Yuanyun and Collins, Jennifer A and Ye, Min Li and Sturrock, Aaron and Leavitt, Blair R and Schrum, Adam G and Hayden, Michael R

DOI: 10.1038/srep12166

Huntington disease

Nature Reviews. Disease Primers

Bates, Gillian P and Dorsey, Ray and Gusella, James F and Hayden, Michael R and Kay, Chris and Leavitt, Blair R and Nance, Martha and Ross, Christopher A and Scahill, Rachael I and Wetzel, Ronald and Wild, Edward J and Tabrizi, Sarah J

DOI: 10.1038/nrdp.2015.5

Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington's disease patients

The Journal of clinical investigation

Wild, Edward J and Boggio, Roberto and Langbehn, Douglas and Robertson, Nicola and Haider, Salman and Miller, James R C and Zetterberg, Henrik and Leavitt, Blair R and Kuhn, Rainer and Tabrizi, Sarah J and Macdonald, Douglas and Weiss, Andreas

DOI: 10.1172/jci80743

Proteolytic degradation of neuropeptide Y (NPY) from head to toe: Identification of novel NPY-cleaving peptidases and potential drug interactions in CNS and Periphery

Journal of neurochemistry

Wagner, Leona and Wolf, Raik and Zeitschel, Ulrike and Rossner, Steffen and Petersn, sa and Leavitt, Blair R and Kstner, Florian and Rothermundt, Matthias and Grtner, Ulf-Torsten and Gndel, Daniel and Schlenzig, Dagmar and Frerker, Nadine and Schade, Jutta and Manhart, Susanne and Rahfeld, Jens-Ulrich and Demuth, Hans-Ulrich and von Hrsten, Stephan

DOI: 10.1111/jnc.13378

The impact of occipital lobe cortical thickness on cognitive task performance: An investigation in Huntington's Disease

Neuropsychologia

Johnson, Eileanoir B and Rees, Elin M and Labuschagne, Izelle and Durr, Alexandra and Leavitt, Blair R and Roos, Raymund A C and Reilmann, Ralf and Johnson, Hans and Hobbs, Nicola Z and Langbehn, Douglas R and Stout, Julie C and Tabrizi, Sarah J and Scahill, Rachael I and {TRACK-HD investigators}

DOI: 10.1016/j.neuropsychologia.2015.10.033

Safety, tolerability, and efficacy of PBT2 in Huntington's disease: a phase 2, randomised, double-blind, placebo-controlled trial.

The Lancet. Neurology

DOI: 10.1016/s1474-4422(14)70262-5 PubMed: 25467848

11 / 2014

Characterisation of immune cell function in fragment and full-length Huntington's disease mouse models.

Neurobiology of disease

DOI: 10.1016/j.nbd.2014.10.012 PubMed: 25447230

10 / 2014

Huntington's disease: a field on the move. Introduction.

Movement disorders : official journal of the Movement Disorder Society

DOI: 10.1002/mds.26017 PubMed: 25164859

08 / 2014

Iron dysregulation in Huntington's disease.

Journal of neurochemistry

DOI: 10.1111/jnc.12739 PubMed: 24717009

05 / 2014

The catalytic function of hormone-sensitive lipase is essential for fertility in male mice.

Endocrinology

DOI: 10.1210/en.2014-1031 PubMed: 24797631

05 / 2014

Correction of inter-scanner and within-subject variance in structural MRI based automated diagnosing.

NeuroImage

DOI: 10.1016/j.neuroimage.2014.04.057 PubMed: 24791746

04 / 2014

Huntington disease: natural history, biomarkers and prospects for therapeutics.

Nature reviews. Neurology

DOI: 10.1038/nrneurol.2014.24 PubMed: 24614516

03 / 2014

The potential of composite cognitive scores for tracking progression in Huntington's disease.

Journal of Huntington's disease

DOI: 10.3233/jhd-140101 PubMed: 25062862

01 / 2014

Progranulin in neurodegenerative disease

Trends in neurosciences

Petkau, Terri L and Leavitt, Blair R

DOI: 10.1016/j.tins.2014.04.003

Diagnostic criteria for Huntington's disease based on natural history

Movement disorders : official journal of the Movement Disorder Society

Reilmann, Ralf and Leavitt, Blair R and Ross, Christopher A

DOI: 10.1002/mds.26011

Aquatherapy for neurodegenerative disorders

Journal of Huntington's disease

Plecash, Alyson R and Leavitt, Blair R

DOI: 10.3233/jhd-140010

p53 increases caspase-6 expression and activation in muscle tissue expressing mutant huntingtin

Human molecular genetics

Ehrnhoefer, Dagmar E and Skotte, Niels H and Ladha, Safia and Nguyen, Yen T N and Qiu, Xiaofan and Deng, Yu and Huynh, Khuong T and Engemann, Sabine and Nielsen, Signe M and Becanovic, Kristina and Leavitt, Blair R and Hasholt, Lis and Hayden, Michael R

DOI: 10.1093/hmg/ddt458

Clinical utility gene card for: Huntington's disease.

European journal of human genetics : EJHG

DOI: 10.1038/ejhg.2013.206 PubMed: 24105375

10 / 2013

A systematic review and meta-analysis of clinical variables used in Huntington disease research.

Movement disorders : official journal of the Movement Disorder Society

DOI: 10.1002/mds.25663 PubMed: 24142393

10 / 2013

We are pleased to introduce this next volume of the Journal of Huntington's Disease. Introduction.

Journal of Huntington's disease

DOI: 10.3233/jhd-130003 PubMed: 25057106

01 / 2013

A randomized, double-blind, placebo-controlled study of latrepirdine in patients with mild to moderate Huntington disease

JAMA neurology

{HORIZON Investigators of the Huntington Study Group and European Huntington's Disease Network}

DOI: 10.1001/2013.jamaneurol.382

The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: the next therapeutic frontier)

Alzheimer's & dementia : the journal of the Alzheimer's Association

Boxer, Adam L and Gold, Michael and Huey, Edward and Hu, William T and Rosen, Howard and Kramer, Joel and Gao, Fen-Biao and Burton, Edward A and Chow, Tiffany and Kao, Aimee and Leavitt, Blair R and Lamb, Bruce and Grether, Megan and Knopman, David and Cairns, Nigel J and Mackenzie, Ian R and Mitic, Laura and Roberson, Erik D and Van Kammen, Daniel and Cantillon, Marc and Zahs, Kathleen and Jackson, George and Salloway, Stephen and Morris, John and Tong, Gary and Feldman, Howard and Fillit, Howard and Dickinson, Susan and Khachaturian, Zaven S and Sutherland, Margaret and Abushakra, Susan and Lewcock, Joseph and Farese, Robert and Kenet, Robert O and Laferla, Frank and Perrin, Steve and Whitaker, Steve and Honig, Lawrence and Mesulam, Marsel M and Boeve, Brad and Grossman, Murray and Miller, Bruce L and Cummings, Jeffrey L

DOI: 10.1016/j.jalz.2012.03.003

Clinical impairment in premanifest and early Huntington's disease is associated with regionally specific atrophy

Human brain mapping

Scahill, Rachael I and Hobbs, Nicola Z and Say, Miranda J and Bechtel, Natalie and Henley, Susie M D and Hyare, Harpreet and Langbehn, Douglas R and Jones, Rebecca and Leavitt, Blair R and Roos, Raymund A C and Durr, Alexandra and Johnson, Hans and Lehricy, Stphane and Craufurd, David and Kennard, Christopher and Hicks, Stephen L and Stout, Julie C and Reilmann, Ralf and Tabrizi, Sarah J and {TRACK-HD investigators}

DOI: 10.1002/hbm.21449

Sensitivity to neurotoxic stress is not increased in progranulin-deficient mice

Neurobiology of aging

Petkau, Terri L and Zhu, Shanshan and Lu, Ge and Fernando, Sarah and Cynader, Max and Leavitt, Blair R

DOI: 10.1016/j.neurobiolaging.2013.04.019

Progranulin promotes activation of microglia/macrophage after pilocarpine-induced status epilepticus

Brain research

Zhu, Shanshan and Tai, Chao and Petkau, Terri L and Zhang, Si and Liao, Chengyong and Dong, Zhifang and Wen, Wendy and Chang, Qing and Tian Wang, Yu and MacVicar, Brian A and Leavitt, Blair R and Jia, William and Cynader, Max S

DOI: 10.1016/j.brainres.2013.07.023

Postnatal muscle modification by myogenic factors modulates neuropathology and survival in an ALS mouse model

Nature communications

Park, Kevin H J and Franciosi, Sonia and Leavitt, Blair R

DOI: 10.1038/ncomms3906

Age-dependent alterations of the kynurenine pathway in the YAC128 mouse model of Huntington disease

Journal of neurochemistry

Mazarei, Gelareh and Budac, David P and Lu, Ge and Adomat, Hans and Tomlinson Guns, Emma S and Mller, Thomas and Leavitt, Blair R

DOI: 10.1111/jnc.12350

Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data

The Lancet. Neurology

Tabrizi, Sarah J and Scahill, Rachael I and Owen, Gail and Durr, Alexandra and Leavitt, Blair R and Roos, Raymund A and Borowsky, Beth and Landwehrmeyer, Bernhard and Frost, Chris and Johnson, Hans and Craufurd, David and Reilmann, Ralf and Stout, Julie C and Langbehn, Douglas R and {TRACK-HD Investigators}

DOI: 10.1016/s1474-4422(13)70088-7

Corpus callosal atrophy in premanifest and early Huntington's disease

Journal of Huntington's disease

Crawford, Helen E and Hobbs, Nicola Z and Keogh, Ruth and Langbehn, Douglas R and Frost, Chris and Johnson, Hans and Landwehrmeyer, Bernhard and Reilmann, Ralf and Craufurd, David and Stout, Julie C and Durr, Alexandra and Leavitt, Blair R and Roos, Raymund A C and Tabrizi, Sarah J and Scahill, Rachael I and {TRACK-HD Investigators}'s disease

DOI: 10.3233/jhd-130077

8OHdG is not a biomarker for Huntington disease state or progression

Neurology

Borowsky, Beth and Warner, John and Leavitt, Blair R and Tabrizi, Sarah J and Roos, Raymund A C and Durr, Alexandra and Becker, Chris and Sampaio, Cristina and Tobin, Allan J and Schulman, Howard

DOI: 10.1212/wnl.0b013e318293e1a1

The absence of indoleamine 2,3-dioxygenase expression protects against NMDA receptor-mediated excitotoxicity in mouse brain

Experimental neurology

Mazarei, G and Budac, DP and Lu, G and Lee, H and Mller, T and Leavitt, BR

DOI: 10.1016/j.expneurol.2013.08.007

Quality of life in Huntington's disease: a comparative study investigating the impact for those with pre-manifest and early manifest disease, and their partners

Journal of Huntington's disease

Read, Joy and Jones, Rebecca and Owen, Gail and Leavitt, Blair R and Coleman, Allison and Roos, Raymund A C and Dumas, Eve M and Durr, Alexandra and Justo, Damian and Say, Miranda and Stout, Julie C and Tabrizi, Sarah J and Craufurd, David and {TRACK-HD investigators}'s disease

DOI: 10.3233/jhd-130051

Frontotemporal degeneration, the next therapeutic frontier: molecules and animal models for frontotemporal degeneration drug development.

Alzheimer's & dementia : the journal of the Alzheimer's Association

DOI: 10.1016/j.jalz.2012.03.002 PubMed: 23043900

10 / 2012

8OHdG as a marker for Huntington disease progression.

Neurobiology of disease

DOI: 10.1016/j.nbd.2012.02.012 PubMed: 22414782

03 / 2012

Decreasing Levels of the cdk5 Activators, p25 and p35, Reduces Excitotoxicity in Striatal Neurons.

Journal of Huntington's disease

DOI: 10.3233/jhd-2012-129000 PubMed: 24353748

01 / 2012

Synaptic dysfunction in progranulin-deficient mice

Neurobiology of disease

Petkau, Terri L and Neal, Scott J and Milnerwood, Austen and Mew, Ada and Hill, Austin M and Orban, Paul and Gregg, Jenny and Lu, Ge and Feldman, Howard H and Mackenzie, Ian R A and Raymond, Lynn A and Leavitt, Blair R

DOI: 10.1016/j.nbd.2011.10.016

Forkhead box protein p1 is a transcriptional repressor of immune signaling in the CNS: implications for transcriptional dysregulation in Huntington disease

Human molecular genetics

Tang, Bin and Becanovic, Kristina and Desplats, Paula A and Spencer, Brian and Hill, Austin M and Connolly, Colum and Masliah, Eliezer and Leavitt, Blair R and Thomas, Elizabeth A

DOI: 10.1093/hmg/dds132

Evaluation of longitudinal 12 and 24 month cognitive outcomes in premanifest and early Huntington's disease

Journal of neurology, neurosurgery, and psychiatry

Stout, Julie C and Jones, Rebecca and Labuschagne, Izelle and O'Regan, Alison M and Say, Miranda J and Dumas, Eve M and Queller, Sarah and Justo, Damian and Santos, Rachelle Dar and Coleman, Allison and Hart, Ellen P and Drr, Alexandra and Leavitt, Blair R and Roos, Raymund A and Langbehn, Doug R and Tabrizi, Sarah J and Frost, Chris

DOI: 10.1136/jnnp-2011-301940

Age-dependent neurovascular abnormalities and altered microglial morphology in the YAC128 mouse model of Huntington disease

Neurobiology of disease

Franciosi, Sonia and Ryu, Jae K and Shim, Yaein and Hill, Austin and Connolly, Colum and Hayden, Michael R and McLarnon, James G and Leavitt, Blair R

DOI: 10.1016/j.nbd.2011.09.003

Visual Working Memory Impairment in Premanifest Gene-Carriers and Early Huntington's Disease

Journal of Huntington's disease

Dumas, Eve M and Say, Miranda J and Jones, Rebecca and Labuschagne, Izelle and O'Regan, Alison M and Hart, Ellen P and van den Bogaard, Simon J A and Queller, Sarah and Justo, Damian and Coleman, Allison and Dar Santos, Rachelle C and Drr, Alexandra and Leavitt, Blair R and Tabrizi, Sarah J and Roos, Raymund A C and Stout, Julie C

DOI: 10.3233/jhd-2012-120010

Journal of Huntington's Disease

Journal of Huntington's disease

Leavitt, Blair R and Thompson, Leslie M

DOI: 10.3233/jhd-2012-120001

Cystamine and ethyl-eicosapentaenoic acid treatment fail to prevent malonate-induced striatal toxicity in mice.

Neurobiology of aging

DOI: 10.1016/j.neurobiolaging.2011.05.020 PubMed: 21741126

07 / 2011

Development of biomarkers for Huntington's disease.

The Lancet. Neurology

DOI: 10.1016/s1474-4422(11)70070-9 PubMed: 21601164

06 / 2011

YB-1 bridges neural stem cells and brain tumor-initiating cells via its roles in differentiation and cell growth

Cancer research

Fotovati, Abbas and Abu-Ali, Samah and Wang, Pei-Shan and Deleyrolle, Loic P and Lee, Cathy and Triscott, Joanna and Chen, James Y and Franciosi, Sonia and Nakamura, Yasuhiro and Sugita, Yasuo and Uchiumi, Takeshi and Kuwano, Michihiko and Leavitt, Blair R and Singh, Sheila K and Jury, Alexa and Jones, Chris and Wakimoto, Hiroaki and Reynolds, Brent A and Pallen, Catherine J and Dunn, Sandra E

DOI: 10.1158/0008-5472.can-10-2805

Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis

The Lancet. Neurology

Tabrizi, Sarah J and Scahill, Rachael I and Durr, Alexandra and Roos, Raymund Ac and Leavitt, Blair R and Jones, Rebecca and Landwehrmeyer, G Bernhard and Fox, Nick C and Johnson, Hans and Hicks, Stephen L and Kennard, Christopher and Craufurd, David and Frost, Chris and Langbehn, Douglas R and Reilmann, Ralf and Stout, Julie C and {TRACK-HD Investigators}

DOI: 10.1016/s1474-4422(10)70276-3

The structural involvement of the cingulate cortex in premanifest and early Huntington's disease

Movement disorders : official journal of the Movement Disorder Society

Hobbs, Nicola Z and Pedrick, Amy V and Say, Miranda J and Frost, Chris and Dar Santos, Rachelle and Coleman, Allison and Sturrock, Aaron and Craufurd, David and Stout, Julie C and Leavitt, Blair R and Barnes, Josephine and Tabrizi, Sarah J and Scahill, Rachael I

DOI: 10.1002/mds.23747

Magnetic resonance spectroscopy biomarkers in premanifest and early Huntington disease.

Neurology

DOI: 10.1212/wnl.0b013e3181fc27e4 PubMed: 21060093

11 / 2010

Full-length huntingtin levels modulate body weight by influencing insulin-like growth factor 1 expression

Human molecular genetics

Pouladi, Mahmoud A and Xie, Yuanyun and Skotte, Niels Henning and Ehrnhoefer, Dagmar E and Graham, Rona K and Kim, Jeong Eun and Bissada, Nagat and Yang, X William and Paganetti, Paolo and Friedlander, Robert M and Leavitt, Blair R and Hayden, Michael R

DOI: 10.1093/hmg/ddq026

Progranulin expression in the developing and adult murine brain

The Journal of comparative neurology

Petkau, Terri L and Neal, SJ and Orban, PC and MacDonald, JL and Hill, AM and Lu, G and Feldman, HH and Mackenzie, I R A and Leavitt, BR

DOI: 10.1002/cne.22430

Transcriptional changes in Huntington disease identified using genome-wide expression profiling and cross-platform analysis

Human molecular genetics

Becanovic, Kristina and Pouladi, Mahmoud A and Lim, Raymond S and Kuhn, Alexandre and Pavlidis, Paul and Luthi-Carter, Ruth and Hayden, Michael R and Leavitt, Blair R

DOI: 10.1093/hmg/ddq018

The clinical and genetic features of Huntington disease

Journal of geriatric psychiatry and neurology

Sturrock, Aaron and Leavitt, Blair R

DOI: 10.1177/0891988710383573

Tapping linked to function and structure in premanifest and symptomatic Huntington disease

Neurology

Bechtel, N and Scahill, RI and Rosas, HD and Acharya, T and van den Bogaard, S J A and Jauffret, C and Say, MJ and Sturrock, A and Johnson, H and Onorato, CE and Salat, DH and Durr, A and Leavitt, BR and Roos, R A C and Landwehrmeyer, GB and Langbehn, DR and Stout, JC and Tabrizi, SJ and Reilmann, R

DOI: 10.1212/wnl.0b013e3182020123

Phosphorylation of huntingtin at Ser421 in YAC128 neurons is associated with protection of YAC128 neurons from NMDA-mediated excitotoxicity and is modulated by PP1 and PP2A

The Journal of neuroscience : the official journal of the Society for Neuroscience

Metzler, Martina and Gan, Lu and Mazarei, Gelareh and Graham, Rona K and Liu, Lili and Bissada, Nagat and Lu, Ge and Leavitt, Blair R and Hayden, Michael R

DOI: 10.1523/jneurosci.1589-10.2010

Expression analysis of novel striatal-enriched genes in Huntington disease.

Human molecular genetics

DOI: 10.1093/hmg/ddp527 PubMed: 19934114

11 / 2009

Gender differences in expression of the human caspase-12 long variant determines susceptibility to Listeria monocytogenes infection

Proceedings of the National Academy of Sciences of the United States of America

Yeretssian, Garabet and Doiron, Karine and Shao, Wei and Leavitt, Blair R and Hayden, Michael R and Nicholson, Donald W and Saleh, Maya

DOI: 10.1073/pnas.0813362106

Differential susceptibility to excitotoxic stress in YAC128 mouse models of Huntington disease between initiation and progression of disease

The Journal of neuroscience : the official journal of the Society for Neuroscience

Graham, Rona K and Pouladi, Mahmoud A and Joshi, Prasad and Lu, Ge and Deng, Yu and Wu, Nan-Ping and Figueroa, Bryan E and Metzler, Martina and Andr, Vronique M and Slow, Elizabeth J and Raymond, Lynn and Friedlander, Robert and Levine, Michael S and Leavitt, Blair R and Hayden, Michael R

DOI: 10.1523/jneurosci.5473-08.2009

Brain-specific proteins decline in the cerebrospinal fluid of humans with Huntington disease

Molecular & cellular proteomics : MCP

Fang, Qiaojun and Strand, Andrew and Law, Wendy and Faca, Vitor M and Fitzgibbon, Matthew P and Hamel, Nathalie and Houle, Benoit and Liu, Xin and May, Damon H and Poschmann, Gereon and Roy, Line and Sthler, Kai and Ying, Wantao and Zhang, Jiyang and Zheng, Zhaobin and Bergeron, John J M and Hanash, Sam and He, Fuchu and Leavitt, Blair R and Meyer, Helmut E and Qian, Xiaohong and McIntosh, Martin W

DOI: 10.1074/mcp.m800231-mcp200

Age-dependent alterations of corticostriatal activity in the YAC128 mouse model of Huntington disease

The Journal of neuroscience : the official journal of the Society for Neuroscience

Joshi, Prasad R and Wu, Nan-Ping and Andr, Vronique M and Cummings, Damian M and Cepeda, Carlos and Joyce, John A and Carroll, Jeffrey B and Leavitt, Blair R and Hayden, Michael R and Levine, Michael S and Bamford, Nigel S

DOI: 10.1523/jneurosci.5687-08.2009

Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data

The Lancet. Neurology

Tabrizi, Sarah J and Langbehn, Douglas R and Leavitt, Blair R and Roos, Raymund Ac and Durr, Alexandra and Craufurd, David and Kennard, Christopher and Hicks, Stephen L and Fox, Nick C and Scahill, Rachael I and Borowsky, Beth and Tobin, Allan J and Rosas, H Diana and Johnson, Hans and Reilmann, Ralf and Landwehrmeyer, Bernhard and Stout, Julie C and {TRACK-HD investigators}

DOI: 10.1016/s1474-4422(09)70170-x

Tetrabenazine

Nature reviews. Drug discovery

Hayden, Michael R and Leavitt, Blair R and Yasothan, Uma and Kirkpatrick, Peter

DOI: 10.1038/nrd2784

A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease.

The Journal of experimental medicine

DOI: 10.1084/jem.20080178 PubMed: 18625748

07 / 2008

Re: Autopsy-proven Huntington's disease with 29 trinucleotide repeats

Movement disorders : official journal of the Movement Disorder Society

Semaka, Alicia and Warby, Simon and Leavitt, Blair R and Hayden, Michael R

DOI: 10.1002/mds.21820

Cocaine- and amphetamine-regulated transcript is increased in Huntington disease.

Movement disorders : official journal of the Movement Disorder Society

DOI: 10.1002/mds.21447 PubMed: 17722045

10 / 2007

Proteomic profiling of plasma in Huntington's disease reveals neuroinflammatory activation and biomarker candidates.

Journal of proteome research

DOI: 10.1021/pr0700753 PubMed: 17552550

06 / 2007

Chapter 15 Juvenile amyotrophic lateral sclerosis.

Handbook of clinical neurology

DOI: 10.1016/s0072-9752(07)80018-2 PubMed: 18808900

01 / 2007

CAG-encoded polyglutamine length polymorphism in the human genome

BMC genomics

Butland, Stefanie L and Devon, Rebecca S and Huang, Yong and Mead, Carri-Lyn and Meynert, Alison M and Neal, Scott J and Lee, Soo Sen and Wilkinson, Anna and Yang, George S and Yuen, Macaire M S and Hayden, Michael R and Holt, Robert A and Leavitt, Blair R and Ouellette, B F Francis

DOI: 10.1186/1471-2164-8-126

Testicular degeneration in Huntington disease

Neurobiology of disease

Van Raamsdonk, Jeremy M and Murphy, Zoe and Selva, David M and Hamidizadeh, Reza and Pearson, Jacqueline and Petersn, Asa and Bjrkqvist, Maria and Muir, Cameron and Mackenzie, Ian R and Hammond, Geoffrey L and Vogl, A Wayne and Hayden, Michael R and Leavitt, Blair R

DOI: 10.1016/j.nbd.2007.01.006

Ataxia and the role of antigliadin antibodies

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques

Wong, D and Dwinnel, M and Schulzer, M and Nimmo, M and Leavitt, BR and Spacey, SD

DOI: 10.1017/s031716710000603x

Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage

Human molecular genetics

Kuhn, Alexandre and Goldstein, Darlene R and Hodges, Angela and Strand, Andrew D and Sengstag, Thierry and Kooperberg, Charles and Becanovic, Kristina and Pouladi, Mahmoud A and Sathasivam, Kirupa and Cha, Jang-Ho J and Hannan, Anthony J and Hayden, Michael R and Leavitt, Blair R and Dunnett, Stephen B and Ferrante, Robert J and Albin, Roger and Shelbourne, Peggy and Delorenzi, Mauro and Augood, Sarah J and Faull, Richard L M and Olson, James M and Bates, Gillian P and Jones, Lesley and Luthi-Carter, Ruth

DOI: 10.1093/hmg/ddm133

Phenotypic abnormalities in the YAC128 mouse model of Huntington disease are penetrant on multiple genetic backgrounds and modulated by strain.

Neurobiology of disease

DOI: 10.1016/j.nbd.2006.12.010 PubMed: 17276692

12 / 2006

Als2-deficient mice exhibit disturbances in endosome trafficking associated with motor behavioral abnormalities.

Proceedings of the National Academy of Sciences of the United States of America

DOI: 10.1073/pnas.0510197103 PubMed: 16769894

06 / 2006

Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice.

Neurobiology of disease

DOI: 10.1016/j.nbd.2006.02.011 PubMed: 16697652

05 / 2006

Wild-type huntingtin protects neurons from excitotoxicity.

Journal of neurochemistry

DOI: 10.1111/j.1471-4159.2005.03605.x PubMed: 16417581

01 / 2006

Cerebrospinal fluid levels of orexin-A are not a clinically useful biomarker for Huntington disease

Clinical genetics

Bjrkqvist, M and Petersn, A and Nielsen, J and Ecker, D and Mulder, H and Hayden, MR and Landwehrmeyer, B and Brundin, P and Leavitt, BR

DOI: 10.1111/j.1399-0004.2006.00636.x

Is tetrabenazine safe and effective for suppressing chorea in Huntington's disease?

Nature clinical practice. Neurology

Leavitt, Blair R and Hayden, Michael R

DOI: 10.1038/ncpneuro0299

Striatal neuronal apoptosis is preferentially enhanced by NMDA receptor activation in YAC transgenic mouse model of Huntington disease

Neurobiology of disease

Shehadeh, Jacqueline and Fernandes, Herman B and Zeron Mullins, Melinda M and Graham, Rona K and Leavitt, Blair R and Hayden, Michael R and Raymond, Lynn A

DOI: 10.1016/j.nbd.2005.08.001

Huntingtin inhibits caspase-3 activation

The EMBO journal

Zhang, Yu and Leavitt, Blair R and van Raamsdonk, Jeremy M and Dragatsis, Ioannis and Goldowitz, Dan and MacDonald, Marcy E and Hayden, Michael R and Friedlander, Robert M

DOI: 10.1038/sj.emboj.7601445

Familial frontotemporal dementia with neuronal intranuclear inclusions is not a polyglutamine expansion disease

BMC neurology

Mackenzie, Ian R and Butland, Stefanie L and Devon, Rebecca S and Dwosh, Emily and Feldman, Howard and Lindholm, Caroline and Neal, Scott J and Ouellette, B F Francis and Leavitt, Blair R

DOI: 10.1186/1471-2377-6-32

Wild-type huntingtin ameliorates striatal neuronal atrophy but does not prevent other abnormalities in the YAC128 mouse model of Huntington disease

BMC neuroscience

Van Raamsdonk, Jeremy M and Pearson, Jacqueline and Murphy, Zoe and Hayden, Michael R and Leavitt, Blair R

DOI: 10.1186/1471-2202-7-80

Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin

Cell

Graham, Rona K and Deng, Yu and Slow, Elizabeth J and Haigh, Brendan and Bissada, Nagat and Lu, Ge and Pearson, Jacqueline and Shehadeh, Jacqueline and Bertram, Lisa and Murphy, Zoe and Warby, Simon C and Doty, Crystal N and Roy, Sophie and Wellington, Cheryl L and Leavitt, Blair R and Raymond, Lynn A and Nicholson, Donald W and Hayden, Michael R

DOI: 10.1016/j.cell.2006.04.026

Body weight is modulated by levels of full-length huntingtin

Human molecular genetics

Van Raamsdonk, Jeremy M and Gibson, William T and Pearson, Jacqueline and Murphy, Zoe and Lu, Ge and Leavitt, Blair R and Hayden, Michael R

DOI: 10.1093/hmg/ddl072

Levels of mutant huntingtin influence the phenotypic severity of Huntington disease in YAC128 mouse models.

Neurobiology of disease

DOI: 10.1016/j.nbd.2005.08.007 PubMed: 16230019

10 / 2005

Loss of wild-type huntingtin influences motor dysfunction and survival in the YAC128 mouse model of Huntington disease

Human molecular genetics

Van Raamsdonk, Jeremy M and Pearson, Jacqueline and Rogers, Daniel A and Bissada, Nagat and Vogl, A Wayne and Hayden, Michael R and Leavitt, Blair R

DOI: 10.1093/hmg/ddi147

Ethyl-EPA treatment improves motor dysfunction, but not neurodegeneration in the YAC128 mouse model of Huntington disease

Experimental neurology

Van Raamsdonk, Jeremy M and Pearson, Jacqueline and Rogers, Daniel A and Lu, Ge and Barakauskas, Vilte E and Barr, Alasdair M and Honer, William G and Hayden, Michael R and Leavitt, Blair R

DOI: 10.1016/j.expneurol.2005.07.021

Cross-species characterization of the ALS2 gene and analysis of its pattern of expression in development and adulthood

Neurobiology of disease

Devon, Rebecca S and Schwab, Claudia and Topp, Justin D and Orban, Paul C and Yang, Yu-Zhou and Pape, Terry D and Helm, Jeffrey R and Davidson, Tara-Lynne and Rogers, Daniel A and Gros-Louis, Francois and Rouleau, Guy and Horazdovsky, Bruce F and Leavitt, Blair R and Hayden, Michael R

DOI: 10.1016/j.nbd.2004.10.002

Cognitive dysfunction precedes neuropathology and motor abnormalities in the YAC128 mouse model of Huntington's disease

The Journal of neuroscience : the official journal of the Society for Neuroscience

Van Raamsdonk, Jeremy M and Pearson, Jacqueline and Slow, Elizabeth J and Hossain, Sazzad M and Leavitt, Blair R and Hayden, Michael R

DOI: 10.1523/jneurosci.0590-05.2005

Treatment of YAC128 mice and their wild-type littermates with cystamine does not lead to its accumulation in plasma or brain: implications for the treatment of Huntington disease

Journal of neurochemistry

Pinto, John T and Van Raamsdonk, Jeremy M and Leavitt, Blair R and Hayden, Michael R and Jeitner, Thomas M and Thaler, Howard T and Krasnikov, Boris F and Cooper, Arthur J L

DOI: 10.1111/j.1471-4159.2005.03255.x

Satellog: a database for the identification and prioritization of satellite repeats in disease association studies

BMC bioinformatics

Missirlis, Perseus I and Mead, Carri-Lyn R and Butland, Stefanie L and Ouellette, B F Francis and Devon, Rebecca S and Leavitt, Blair R and Holt, Robert A

DOI: 10.1186/1471-2105-6-145

Ethyl-EPA in Huntington disease: a double-blind, randomized, placebo-controlled trial

Neurology

Puri, BK and Leavitt, BR and Hayden, MR and Ross, CA and Rosenblatt, A and Greenamyre, JT and Hersch, S and Vaddadi, KS and Sword, A and Horrobin, DF and Manku, M and Murck, H

DOI: 10.1212/01.wnl.0000169025.09670.6d

Selective degeneration and nuclear localization of mutant huntingtin in the YAC128 mouse model of Huntington disease

Human molecular genetics

Van Raamsdonk, Jeremy M and Murphy, Zoe and Slow, Elizabeth J and Leavitt, Blair R and Hayden, Michael R

DOI: 10.1093/hmg/ddi407

Cystamine treatment is neuroprotective in the YAC128 mouse model of Huntington disease

Journal of neurochemistry

Van Raamsdonk, Jeremy M and Pearson, Jacqueline and Bailey, Craig D C and Rogers, Daniel A and Johnson, Gail V W and Hayden, Michael R and Leavitt, Blair R

DOI: 10.1111/j.1471-4159.2005.03357.x

Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions

Proceedings of the National Academy of Sciences of the United States of America

Slow, Elizabeth J and Graham, Rona K and Osmand, Alexander P and Devon, Rebecca S and Lu, Ge and Deng, Yu and Pearson, Jacqui and Vaid, Kuljeet and Bissada, Nagat and Wetzel, Ronald and Leavitt, Blair R and Hayden, Michael R

DOI: 10.1073/pnas.0503634102

Potentiation of NMDA receptor-mediated excitotoxicity linked with intrinsic apoptotic pathway in YAC transgenic mouse model of Huntington's disease.

Molecular and cellular neurosciences

DOI: 10.1016/j.mcn.2003.11.014 PubMed: 15033175

03 / 2004

Novel ventriculo-peritoneal shunt in Alzheimer's disease cerebrospinal fluid biomarkers.

Expert review of neurotherapeutics

DOI: 10.1586/14737175.4.1.97 PubMed: 15853620

01 / 2004

Increased huntingtin protein length reduces the number of polyglutamine-induced gene expression changes in mouse models of Huntington's disease.

Human molecular genetics

DOI: 10.1093/hmg/11.17.1939 PubMed: 12165556

08 / 2002

Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease.

Science (New York, N.Y.)

DOI: 10.1126/science.1059581 PubMed: 11408619

06 / 2001

A one-hit model of cell death in inherited neuronal degenerations.

Nature

DOI: 10.1038/35018098 PubMed: 10910361

07 / 2000

Huntington disease: new insights on the role of huntingtin cleavage.

Journal of neural transmission. Supplementum

DOI: 10.1007/978-3-7091-6284-2_1 PubMed: 11128600

01 / 2000

Differentiation of transplanted neural precursors varies regionally in adults striatum.

Neuroreport

DOI: 10.1097/00001756-199912160-00045 PubMed: 10716243

12 / 1999

A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration.

Neuron

DOI: 10.1016/s0896-6273(00)80764-3 PubMed: 10402204

05 / 1999

Current Projects

The Laboratory for Experimental Therapeutics in Animal Models of Human Disease at the Centre for Molecular Medicine and Therapeutics (CMMT) is dedicated to developing new treatments for hereditary brain diseases, such as Huntington’s disease, Fragile X, and Frontotemporal dementia. Molecular genetic tools are used to generate transgenic animal models of these diseases. New approaches to treatment are then tested in these models, with the goal of accelerating the progress of new treatments from the bench to the clinic. This facility’s resources and expertise provide the basis for collaborative projects with scientists worldwide.

An important mouse model used in my laboratory is a Yeast Artificial chromosome (YAC) transgenic mouse model of Huntington’s Disease (HD) originally developed in Michael Hayden's laboratory at the CMMT. This mouse model faithfully replicates key features of the human disease; specifically these mice develop age-related motor dysfunction, behavioural abnormalities, and selective neurodegeneration of medium spiny neurons of the striatum. YAC transgenic mice have now been generated with the full-length human HD gene containing normal (YAC18) and expanded (YAC46, 72, and 128) CAG repeats. Different lines of transgenic mice have varying copy numbers of the human transgene and express varying amounts of transgenic huntingtin protein. The progressive motor and neurodegenerative phenotype of the YAC128 mouse model of HD makes in vivo screening of novel therapeutic approaches viable.

My laboratory includes a mouse behavioural testing unit allowing phenotypic characterization of large numbers of transgenic mice using a standardized behavioural protocol, as well as a dedicated small animal surgical suite allowing a variety of surgical procedures including administration of stem cells, compounds or gene therapy directly into the CNS. I’ve established a dedicated image analysis suite, stereology system, and automated neuropathology unit for high-throughput quantitative analysis of neurodegeneration in transgenic mouse brains.

Several trials of potential therapeutic agents have now been initiated in our YAC transgenic mouse model. Novel therapeutic approaches effective in our HD model will likely have utility in a broad range of neurodegenerative disorders. We currently are performing CRISPR-based gene therapy experiments using non-viral lipid nanoparticle delivery systems. I also have several ongoing projects investigating the role of wild-type huntingtin in neuronal apoptosis and a possible role for loss of huntingtin function in neurodevelopment and neurodegenerative disease.

In addition to my basic laboratory research, I’m a neurologist with an ongoing clinical practice and clinical research program in neurogenetics, with a focus on hereditary movement disorders, specifically various forms of ataxia and chorea. Together with Dr. Michael Hayden I lead thein post-mortem studies of HD patients as well as clinical research directed at identifying novel forms of CAG repeat disorders. I’m involved in clinical trials of new therapeutics in Huntington’s disease. I’m also the Director of Research at the UBC Centre for HD and Director of the Mouse Facility at the CMMT.

Honours & Awards

Young Investigator Award, Brain Research Centre, University of British Columbia, 1999

Award for Outstanding Achievement by a Postdoctoral Fellow, BC Research Institute for Children’s & Women’s Health, 2001

Michael Smith Foundation for Health Research Career Investigator Award, 2007

Related News

Every day, our researchers work towards breakthroughs to transform the lives of kids in BC and around the world. Learn about our latest innovations and advancements in child health.

Our Research

At BC Children’s, we are making discoveries that save lives and transform health care for children in our province and around the world. Our research portfolio includes basic, clinical, population, and public health research.

EXPLORE OUR RESEARCH

Stay in the Know

Sign up for compelling stories about innovative science, the doctors and researchers who turn ideas into discoveries and treatments, and the kids and families whose lives are changed.

This field is for validation purposes and should be left unchanged.